Abstract:AIM:To investigate the efficacy and safety of combined de novo lamivudine (LAM) and adefovir dipivoxil (ADV) therapy in hepatitis B virus (HBV)-related decompensated liver cirrhosis patients.METHODS:One hundred and forty patients with HBV-related decompensated cirrhosis were recruited, 70 patients were treated with combined LAM and ADV de novo therapy, and the other 70 patients were treated with LAM alone as controls. The follow-up period was 144 wk. All patients with LAM resistance were shifted to ADV.RESULTS:The percentage of HBV-related decompensated cirrhosis patients with undetectable HBV DNA in de novo combination group was 51.6% (33/64), 84.2% (48/57), and 92.3% (49/53) by weeks 48, 96, and 144, respectively. In monotherapy group, HBV DNA negativity rate was 46.1% (30/65), 56.1% (32/57), and 39.2% (20/51) by weeks 48, 96 and 144, respectively. There was a significant difference between the two groups by weeks 96 and 144 (P = 0.012 and 0.001). The hepatitis B e antigen seroconversion rate was 28.1% (9/32), 40.0% (12/30), and 53.6% (15/28) in the combination group by weeks 48, 96 and 144, respectively, and 24.2% (8/33), 31.0% (9/29), and 37.0% (10/27) by weeks 48, 96 and 144, respectively, in monotherapy group. A total of 68.6% (44/64), 84.2% (48/57), and 92.5% (49/53) patients achieved alanine aminotransferase (ALT) normalization by weeks 48, 96 and 144, respectively in the combination group. In monotherpy group, the ALT normalization rate was 64.6% (42/65) by week 48, 73.7% (42/57) by week 96, and 80.4% (41/51) by week 144. No patients in the combination group exhibited detectable resistance for at least 144 wk. The cumulative resistance rate in monotherapy group at weeks 48, 96, and 144 was 20.0%, 36.8%, and 56.9%. Both combination group and monotherapy group demonstrated an improvement in Child-Turcotte Pugh and Model for End-Stage Liver Disease scores at weeks 48, 96, and 144. All patients tolerated both combination and monotherapy. The ceratinine levels and glomerular filtration rate remained normal in all patients during the follow-up period.CONCLUSION:In HBV-related decompensated liver cirrhosis patients, the combined de novo LAM and ADV therapy is more efficacious and safer compared to LAM alone.

Efficacy Analysis of HAART in 52 Cases of Hemophilia with HIV/HCV Coinfection

Efficacy analysis of HAART in 52 cases o hemophilia with HIV/HCV coinfection

Four years clinical analysis of 50 cases of hemophilia patients co-infected by AIDS/HCV treated with active antiretroviral therapy

[Highly Active Antiretroviral Therapy on Liver Function in HIV-positive Children with HBV/HCV Co-Infection].

The effect of different HAART regimens on liver function and HIV load of HIV infected children with HCV co-infection

The Impact of Highly Active Antiretroviral Treatment on the Blood Profiles of Patients with Acquired Immune Deficiency Syndrome

Efficacy and safety of efavirenz-based regimens in human immunodeficiency virus/hepatitis C virus co-infected patients

Efficacy And Safety Of Antiretroviral Regimens Including Raltegravir To Treat Hiv-Infected Patients With Hemophilia

The Effect of Highly Active Antiretroviral Therapy on Liver Function in Human Immunodeficiency Virus-Infected Pediatric Patients with or Without Hepatitis Virus Co-Infection

Antiviral Therapy for HCV in Hemophilia A Patients with HIV-1 Co-Infection

Efficacy and Safety of Pegylated Interferon Alpha‐2a Therapy for Chronic Hepatitis C in HIV‐infected Patients with Haemophilia

Efficacy of Combined Therapy in Patients with Hepatitis B Virus-Related Decompensated Cirrhosis.

[Clinical Impacts of Highly Active Antiretroviral Therapy on Patients of Hemophilia Combined with Acquired Immunodeficiency Syndrome: 6-Year Follow-Up of 39 Cases].

[Peg-Interferon Alfa-2A and Highly Active Antiretroviral Drug Therapy on Hepatitis C Patients with AIDS].

Efficacy of HAART in antiretroviral-na(i)ve patients analyzed by baseline CD4 cell counts

A 72-week on-treatment efficacy of de novo combination of tenofovir plus lamivudine based highly active antiretroviral therapy for HBV-HIV co-infected patients

Evalution of highly active antiretroviral therapy in 182 patients with HIV/AIDS

Efficacy of adefovir dipivoxil in treatment of chronic hepatitis B patients with lamivudine resistance

[The Analyse of Effectiveness in HBeAg-positive Chronic Viral Hepatitis B Treated by Adefovir Dipivoxil Combined with Bicyclol].

Clinical study of hyperlipidemia and fatty liver disease in patients receiving HAART

Biological characteristics and survival analysis in HIV/HCV co-infected patients